|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| Par Pharmaceutical Companies, Inc. | |
||||||||||||||||||||||||||||||||||||||||||||||||
| Par Pharmaceutical Companies, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRX | Last: $27.92 ($+1.55) | Volume: 129,995 | Last Trade: 7/30/2010 3:50:13 PM | ||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Par Pharmaceutical Companies, Inc. Profile | |||||||||||||||||||||||||||||||||||||||||||||||||
| Par Pharmaceutical is a holding company. Through its subsidiaries, Co. is engaged in developing, manufacturing and distributing generic and branded drugs in the U.S. Co.'s product line comprise of generic prescription drugs consisting of about 180 products representing various dosage strengths for more than 80 separate drugs. Co.'s products are manufactured mainly in the solid oral dosage form. In addition, Co. markets several oral suspension products, products in the semi-solid form of a cream and an inhaler product. Co. conducts its businesses through two business segments: generic pharmaceuticals and brand pharmaceuticals. | |||||||||||||||||||||||||||||||||||||||||||||||||
| Par Pharmaceutical Companies, Inc. News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||
|
FDA Approves Strativa Pharmaceuticals' Zuplenz® (ondansetron) Oral Soluble Film WOODCLIFF LAKE, N.J. , July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative,... [more] Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To WOODCLIFF LAKE, N.J. , May 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced that its partner, Glenmark Generics Limited and Glenmark Generics Inc., USA , has entered into a... [more] Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film WOODCLIFF LAKE, N.J. , Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zu... [more] Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 201 WOODCLIFF LAKE, N.J. , Feb. 2 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) announced today that it will host a conference call and live webcast on Wednesday, February 24, 2010 at 8:... [more] Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Au WOODCLIFF LAKE, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced that it has extended the expiration date and increased the purchase price of its previous... [more] Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Agg WOODCLIFF LAKE, N.J., Oct. 14 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced that it has commenced a "Modified Dutch Auction" tender offer for a portion of i... [more] Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres T WOODCLIFF LAKE, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval... [more] Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results Reports Adjusted Q4 EPS of $0.21 WOODCLIFF LAKE, N.J. , March 2 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today reported f... [more] Par Pharmaceutical to Host Fourth Quarter and Full Year 2008 Results Conference Call on March 3 at 9 WOODCLIFF LAKE, N.J. , Feb. 25 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) announced today that it will host a conference call and live webcast on Tuesday,... [more] Par Pharmaceutical to Present at the 27th Annual J.P. Morgan Healthcare Conference WOODCLIFF LAKE, N.J. , Jan. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) will be presenting at the 27th Annual J.P. Morgan Healthcare Conference on Wedne... [more] Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension WOODCLIFF LAKE, N.J. , Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced that the U.S. District Court for the District of New Jersey</spa... [more] Par Pharmaceutical Reports Second Quarter 2008 Results WOODCLIFF LAKE, N.J. , Aug. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ( PRX ) today announced results for the second quarter ended June 28, 2008 .</p... [more] Par Pharmaceutical Reports First Quarter 2008 Results WOODCLIFF LAKE, N.J., May 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. PRX today reported results for the first quarter ended March 29, 2008. Par reported total revenues of $154.9 million and net income of $2.6... [more] Teva Wants the FDA to Do What? Motley Fool: - Mar 5, 2008 If Teva doesn't win its lawsuit, the generic-drug maker will likely have to compete with Par Pharmaceutical ( NYSE: PRX ), Mylan (NYSE: MYL), Barr Labs (NYSE: ... Staying at Par? Motley Fool: - Mar 4, 2008 ... its financial statements, after being behind because of restating earnings from 2006, investors can see how Par Pharmaceutical ( NYSE: PRX ) did in 2007. ... Array BioPharma, Orion Energy Systems and Par Pharmaceutical ... SmallCapInvestor: Array BioPharma, Orion Energy Systems and Par Pharmaceutical ... - Mar 3, 2008 Array BioPharma Inc. (Nasdaq: ARRY), Orion Energy Systems, Inc. (Nasdaq: OESX) and Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) are among the biggest ... Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results PR Newswire (press release): Par Pharmaceutical Companies, Inc. NYSE: PRX today reported fourth quarter and full year 2007 results ended December 31, 2007. ... Strativa Pharmaceuticals, a Division of Par Pharmaceutical ... PR Newswire (press release): Strativa Pharmaceuticals, a Division of Par Pharmaceutical ... , NY - Feb 25, 2008 ... Inc. NYSE: PRX today announced that its development partner, Immtech Pharmaceuticals, Inc. AMEX: IMM has chosen to discontinue the development p Streetinvesting.com: Progressive Following on Par Pharmaceutical ... Trading Markets (press release): Streetinvesting.com: Progressive Following on Par Pharmaceutical ... , CA - Feb 25, 2008 Feb 25th 2008, Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. ( NY MB Alerts: Has added Par Pharmaceutical Companies Inc. to their ... Trading Markets (press release): MB Alerts: Has added Par Pharmaceutical Companies Inc. to their ... , CA - Feb 25, 2008 Monday, February 25, 2008 we have added ( NYSE:PRX ) to our portfolio. The Maybach Financial Group www.maybachfinancial.com will be researching the Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical ... Drug Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE:PRX ) today announced that Melvin Sharoky, MD, ... Par Begins Shipment of Generic Zantac Syrup(R) PR Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) today announced it has entered into a supply and ... Par Pharmaceuticals Signs Supply, Distribution Agreement With ... WebWire (press release): Par Pharmaceuticals Signs Supply, Distribution Agreement With ... , GA - Mar 22, 2007 Par Pharmaceutical Companies, Inc. ( NYSE: PRX - News) today announced it has entered into a supply and distribution agreement with GlaxoSmithKline Par Pharmaceutical To Present at Lehman Brothers' Tenth Annual ... PR Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) will be presenting at the Lehman Brothers Tenth Annual ... Par Pharmaceutical Files Form 10-K/A With SEC PR Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) today filed with the US Securities and Exchange ... Par Pharmaceutical (PRX) Files Form 10-K/A With SEC StreetInsider.com (subscription): , MI - Mar 13, 2007 Par Pharmaceutical Companies, Inc. ( NYSE: PRX - News) today filed with the US Securities and Exchange Commission its 2005 Annual Report on Form 10-K/A that, ... Par Pharmaceutical Returns PAR-101 Marketing Rights to Optimer ... Drug Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE:PRX ) today announced it has returned marketing rights to Difimicin (PAR-101/OPT-80), ... Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical ... PR Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) today announced that Melvin Sharoky, MD, ... New Director at Par Pharmaceutical NJBIZ: , NJ - Mar 8, 2007 Melvin Sharoky has been elected to the board of directors of Par Pharmaceutical Inc. ( NYSE: PRX ). Shares of the Woodcliff Lake-based company were up $0.36, ... Par Pharmaceutical Names Paul Campanelli President, Generics Division PR Newswire (press release): Par Pharmaceutical Companies, Inc. ( NYSE: PRX ) today announced that Paul V. Campanelli has been named ... |
|||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2010 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
